The bill strengthens enforcement against insurer-provider consolidation to protect competition and patient-centered care, but it risks short-term disruption, transaction costs, and reduced plan choices for some Medicare beneficiaries as enforcement and divestitures are carried out.
Hospitals, health systems, and insurers will face stronger antitrust enforcement as the FTC, DOJ, HHS OIG, and state attorneys general can sue and require divestiture, which helps preserve competition and limit insurer-provider consolidation.
Medicare beneficiaries could experience fewer conflicts of interest and better care coordination because limits on insurer-provider integration reduce incentives for overuse and misaligned care decisions.
Medicare Advantage enrollees and regulators gain more transparency and oversight because MA organizations must certify compliance, giving the Secretary and states clearer information on plan conduct.
Owners of integrated provider or insurer entities and affected patients may face short-term disruption and costs because required divestitures can impose transaction costs, revenue loss, and potential changes in provider organization that disrupt continuity of care.
Medicare Advantage enrollees in some areas could lose plan options if MA organizations become ineligible for contracts following enforcement actions, reducing choice for those beneficiaries.
Taxpayers and businesses could incur indirect costs from increased litigation, enforcement, administration of divestitures, and management of disgorged funds.
Based on analysis of 2 sections of legislative text.
Prohibits the same person from owning both health insurers and health care providers (or MSOs), requires divestiture deadlines, and authorizes civil enforcement with disgorgement to aid harmed communities.
Introduced September 17, 2025 by Val Hoyle · Last progress September 17, 2025
Prohibits any person from simultaneously owning, operating, or controlling both a health insurance issuer and any part of a health care provider (or a management services organization that contracts with such a provider). It requires divestiture when such ownership exists at enactment or is acquired later, sets short timelines for divestiture, and creates civil enforcement pathways and remedies including courts-ordered divestiture, cease-and-desist orders, and disgorgement of revenues to a fund used to serve the harmed community. Enforcement can be pursued by the HHS Inspector General, the Department of Justice Antitrust Division, the Federal Trade Commission, or state attorneys general in federal court. The FTC must issue implementing rules and evaluate divestitures for competitive and public-interest effects, and the bill preserves other agencies’ enforcement powers while adding specific reporting and review requirements tied to antitrust processes.